

SciClone Pharmaceuticals to Present at Three Investor Conferences in June

Jefferies 2010 Global Life Sciences Conference on Wednesday, June 9 at 10 am ET; Needham Annual Healthcare Conference on Thursday, June 10 at 1:20 pm ET; ThinkEquity Mid-Year Check up on Healthcare Conference on Wednesday, June 16 at 3:00 pm ET

FOSTER CITY, CA, Jun 03, 2010 (MARKETWIRE via COMTEX News Network) -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will present at three upcoming investor conferences: Jefferies 2010 Global Life Sciences Conference, Needham Annual Healthcare Conference, and ThinkEquity Mid-Year Check up on Healthcare Conference. SciClone's executives will present a corporate overview and business update at each conference.

Jefferies Global Life Sciences Conference

Wednesday, June 9; 10:00 am ET

New York City, NY

Presenter: Gary Titus, Senior Vice President and CFO

Needham Annual Healthcare Conference

Thursday, June 10; 1:20 pm ET

New York City, NY

Presenter: Gary Titus, Senior Vice President and CFO

ThinkEquity Mid-Year Check up on Healthcare Conference

Wednesday, June 16; 3:00 pm ET

New York City, NY

Presenter: Friedhelm Blobel, PhD, President and CEO

To access the live audio webcasts of the presentations, please log on through a link located in the Investor Relations section of SciClone's website at www.sciclone.com.

About SciClone SciClone Pharmaceuticals (NASDAQ: SCLN) is a profit-focused, global specialty pharmaceutical company with a substantial international business and a product portfolio of novel therapies for cancer and infectious diseases. SciClone is focused on continuing international sales growth, a cost-containing clinical development strategy, and overall expense management. ZADAXIN(R) (thymalfasin or thymosin alpha 1) is sold in over 30 countries for the treatment of hepatitis B (HBV) and hepatitis C (HCV), certain cancers and as a vaccine adjuvant. SciClone's pipeline of drug candidates includes thymalfasin, in clinical studies as an enhancer of vaccines; SCV-07 in a phase 2 trial for the delay to onset of severe oral mucositis in patients receiving chemoradiation therapy for the treatment of cancers of the head and neck; and SCV-07 in a phase 2 trial for the treatment of HCV. SciClone has exclusive commercialization and distribution rights to DC Bead(TM) in China, where the product is under regulatory review. The Company also has exclusive commercialization and distribution rights to the anti-nausea drug ondansetron RapidFilm(TM) in China, including Hong Kong and Macau, and Vietnam, for which it will seek regulatory approval. For additional information, please visit www.sciclone.com.

SOURCE: SciClone Pharmaceuticals, Inc.

Copyright 2010 Marketwire, Inc., All rights reserved.

News Provided by COMTEX